Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia

BACKGROUND: Expression of Bcr-Abl in hematopoietic stem cells is sufficient to cause chronic myeloid leukemia (CML) and tyrosine kinase inhibitors (TKI) induce molecular remission in the majority of CML patients. However, the disease driving stem cell population is not fully targeted by TKI therapy,...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrmann, Oliver, Kuepper, Maja Kim, Bütow, Marlena, Costa, Ivan G., Appelmann, Iris, Beier, Fabian, Luedde, Tom, Braunschweig, Till, Koschmieder, Steffen, Brümmendorf, Tim H., Schemionek, Mirle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610865/
https://www.ncbi.nlm.nih.gov/pubmed/31272418
http://dx.doi.org/10.1186/s12885-019-5871-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610865/
https://www.ncbi.nlm.nih.gov/pubmed/31272418
http://dx.doi.org/10.1186/s12885-019-5871-2

Ejemplares similares